Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).

Article  PubMed  Google Scholar 

Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531–550 (2021).

Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018).

Article  CAS  PubMed  Google Scholar 

Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112–116 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wudhikarn, K. et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 10, 79 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Nahas, G. et al. Persistent cytopenias after chimeric antigen receptor t-cell immunotherapy for CD19+ aggressive lymphoma: a single institution experience. Biol. Blood Marrow Transplant. 25, S180 (2019).

Article  Google Scholar 

Fried, S. et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 54, 1643–1650 (2019).

Article  CAS  PubMed  Google Scholar 

Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126–142.e17 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramakrishna, S., Barsan, V. & Mackall, C. Prospects and challenges for use of CAR T cell therapies in solid tumors. Expert Opin. Biol. Ther. 20, 503–516 (2020).

Article  CAS  PubMed  Google Scholar 

Wang, G. et al. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nat. Immunol. 20, 1494–1505 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426–1438.e11 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770–779 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lohmueller, J. J., Ham, J. D., Kvorjak, M. & Finn, O. J. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology 7, e1368604 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Lee, Y. G. et al. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res. 79, 387–396 (2019).

Article  CAS  PubMed  Google Scholar 

Landgraf, K. E. et al. convertibleCARs: a chimeric antigen receptor system for flexible control of activity and antigen targeting. Commun. Biol. 3, 296 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller, I. C. et al. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat. Biomed. Eng. 5, 1348–1359 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, A. Q. et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat. Biomed. Eng. 7, 1113–1128 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park, A. K. et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. 12, eaaz1863 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aalipour, A. et al. Viral delivery of CAR targets to solid tumors enables effective cell therapy. Mol. Ther. Oncolytics 17, 232–240 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vincent, R. L. et al. Probiotic-guided CAR-T cells for solid tumor targeting. Science 382, 211–218 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kunz, P. et al. The structural basis of nanobody unfolding reversibility and thermoresistance. Sci. Rep. 8, 7934 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Ingram, J. R., Schmidt, F. I. & Ploegh, H. L. Exploiting nanobodies’ singular traits. Annu. Rev. Immunol. 36, 695–715 (2018).

Article  CAS  PubMed  Google Scholar 

Peyvandi, F. et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 374, 511–522 (2016).

Article  CAS  PubMed  Google Scholar 

Tiwari, P. M. et al. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat. Commun. 9, 3999 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Movahedi, K. et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 72, 4165–4177 (2012).

Article  CAS  PubMed  Google Scholar 

Keyaerts, M. et al. Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J. Nucl. Med. 57, 27–33 (2016).

Article  CAS  PubMed  Google Scholar 

Nchinda, G. et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118, 1427–1436 (2008).

Article  CAS  PubMed  PubMed Central